News

For trichotillomania, try behavioral therapy before drugs


 

EXPERT ANALYSIS FROM THE PSYCHOPHARMACOLOGY UPDATE INSTITUTE

Dr. Coffey disclosed that she is on the advisory boards of Eli Lilly, Jazz Pharmaceuticals, and Novartis. She has received research support from Boehringer Ingelheim, Bristol-Myers Squibb, CatalystPharma, Eli Lilly, Otsuka Pharmaceutical, and Shire. She is on the speakers bureau for Quintiles.

msullivan@frontlinemedcom.com

Pages

Recommended Reading

Six percent of adolescents report psychotropic use in past month
MDedge Psychiatry
Pediatric epilepsy surgery improved mood, behavior in some patients
MDedge Psychiatry
VIDEO: Brain's iron levels may be ADHD biomarker
MDedge Psychiatry
Teens report increasingly lax attitude about marijuana use
MDedge Psychiatry
FDA warns methylphenidate drugs associated with priapism
MDedge Psychiatry
Exposure therapy trumped supportive counseling for adolescent PTSD
MDedge Psychiatry
Ohio Medicaid data document rising polypharmacy in foster children
MDedge Psychiatry
Perception of safety spurs e-cigarette use in young adults
MDedge Psychiatry
When ADHD doesn’t improve, check medication adherence first
MDedge Psychiatry
Drug therapy for children with autism: No magic bullets yet
MDedge Psychiatry